Sun Pharma has been awarded a rare pediatric disease priority review voucher after being originally denied in 2022

Sun Pharma has been awarded a rare pediatric disease Priority Review Voucher for Sezaby after previously being denied by the FDA in 2022. Sun Pharma won a Court battle against the FDA on their Priority Review Voucher denial in 2022 when Sezaby was approved.

See our previous article on the Sun Pharma vs FDA Court battle